NEW YORK


,


April 15, 2022


/PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of AbbVie Inc. (NYSE: ABBV).

To receive updates on the lawsuit, fill out the form:

The lawsuit seeks to recover losses for shareholders who purchased AbbVie between

April 30, 2021

and August 31, 2021.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until


June 6, 2022


to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

According to a filed complaint, AbbVie Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW

1140 Avenue of the Americas

9th Floor


New York, New York

10036

T: (212) 867-4490

F: (212) 537-5887

View original content:

https://www.prnewswire.com/news-releases/abbv-shareholder-alert-jakubowitz-law-reminds-abbvie-shareholders-of-a-lead-plaintiff-deadline-of-june-6-2022-301526272.html

SOURCE Jakubowitz Law